Life Science Investing Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Life Science Investing Aclaris Therapeutics to Host In-Person and Webcast R&D Day, "Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets", in New York on October 14, 2025
Life Science Investing Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology Congress
E-Power Resources Inc. Announces Tetepisca Flake Graphite Property Delivers High-Value Concentrate Potential, Demonstrating High Recoveries and Premium Flake Size Distribution
